Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr:166:105507.
doi: 10.1016/j.phrs.2021.105507. Epub 2021 Feb 18.

Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma

Ning Zheng  1 , Shaoqin Zhang  2 , Wenda Wu  2 , Nan Zhang  2 , Jichuang Wang  3
Affiliations
Review

Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma

Ning Zheng et al. Pharmacol Res. 2021 Apr.

Abstract

Hepatocellular carcinoma (HCC) is a typical hyper-vascular solid tumor; aberrantly rich in tumor vascular network contributes to its malignancy. Conventional anti-angiogenic therapies seem promising but transitory and incomplete efficacy on HCC. Vasculogenic mimicry (VM) is one of functional microcirculation patterns independent of endothelial vessels which describes the plasticity of highly aggressive tumor cells to form vasculogenic-like networks providing sufficient blood supply for tumor growth and metastasis. As a pivotal alternative mechanism for tumor vascularization when tumor cells undergo lack of oxygen and nutrients, VM has an association with the malignant phenotype and poor clinical outcome for HCC, and may challenge the classic anti-angiogenic treatment of HCC. Current studies have contributed numerous findings illustrating the underlying molecular mechanisms and signaling pathways supporting VM in HCC. In this review, we summarize the correlation between epithelial-mesenchymal transition (EMT), cancer stem cells (CSCs) and VM, the role of hypoxia and extracellular matrix remodeling in VM, the involvement of adjacent non-cancerous cells, cytokines and growth factors in VM, as well as the regulatory influence of non-coding RNAs on VM in HCC. Moreover, we discuss the clinical significance of VM in practice and the potential therapeutic strategies targeting VM for HCC. A better understanding of the mechanism underlying VM formation in HCC may optimize anti-angiogenic treatment modalities for HCC.

Keywords: Arsenic trioxide (PubChem CID: 14888); Cancer stem cells; Curcumin (PubChem CID: 969516); Doxycycline (PubChem CID: 54671203); Epithelial-mesenchymal transition; Fasudil (PubChem CID: 3547); Hepatocellular carcinoma; Incarvine C (PubChem CID: 11222122); Melittin (PubChem CID: 16133648); Molecular signaling and anti-VM therapy; NVP-BEP800 (PubChem CID: 25210273); Non-coding RNAs; Polyphyllin I (PubChem CID: 11018329); Regorafenib (PubChem CID: 11167602); Vasculogenic mimicry.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms

Substances